BICX — BioCorRx Inc.

OTC · Health Care · Health Care Providers & Services · CIK 1443863 ·
Last close
$0.40
Market Cap
$11.62M
52W High
$1.28
52W Low
$0.24
ADV30
2,120
Next earnings
BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. The company offers a substance use disorder recovery program, Beat Addiction Recovery, which includes cognitive behavioral therapy modules, peer support through a mobile application, and medication prescription from an independent treating physician; and the UnCraveRx weight loss management program, a medication-assisted weight loss program that includes access to concierge on-demand wellness specialists. It also develops BICX101, an injectable and implantable naltrexone product; BICX102, a long-acting naltrexone implant that can last several months for opioid dependence and alcohol use disorders; and BICX104, a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of opioid use disorder. The company licenses and distributes its program to healthcare providers and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. was founded in 2009 and is based in Anaheim, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 214,539 189,355 -587,029 -831,227 2,324,865 211,911 13,948,134
Dec 2025 -151,118 185,893 466,284 552,555 2,147,212 139,360 13,674,200
Sep 2025 635,224 276,412 -1,078,457 -1,917,873 7,533,473 287,688 20,297,768
Jun 2025 178,238 178,238 -1,259,650 -1,233,418 6,680,879 111,872 19,694,108

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-2,298,291
Investing CF
Financing CF
$2,349,618
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.38
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-86,649,288
Inventory
$143,425
Receivables
$305,485
ST Investments
EBIT TTM
$-2,647,204
Pretax Income TTM
$-3,508,760
Interest Exp TTM
$861,556
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$876,884
EBITDA
$-4,812,967
Free Cash Flow
$-7,021,148
Enterprise Value
$13,414,982
Total Cash
$211,911
Total Debt
$2,156,317
Shares Out
29,055,547
Trailing EPS
$-0.16
Book Value
$-0.40
ROE
ROA
-66.3%
Div Yield

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 797,244 -2,395,794 -3,440,146 2,147,212 13,674,200 -2,298,291
Dec 2024 7,665 -3,649,229 -5,106,124 385,941 12,741,173 -1,096,254
Dec 2023 89,160 -2,806,820 -3,766,913 388,887 10,341,411 -1,853,282
Dec 2022 213,841 -2,908,499 -4,369,413 766,594 8,968,325 -2,041,773
Dec 2021

TTM Snapshot

Revenues TTM
$659
NetIncome TTM
$-6,752
OpCashFlow TTM
$0
Assets (Latest)
$4,061,511
Forward EPS
$-0.07

Peers — same industry

TickerNameMarket CapLastDaily %
PFHO PACIFIC HEALTH CARE ORGANIZATION INC $12.03M $0.94
BMGL Basel Medical Group Ltd $10.89M $0.58
MRAI Marpai, Inc. $10.88M $0.43
CCM Concord Medical Services Holdings Ltd $13.77M $4.89
MGRX MANGOCEUTICALS, INC. $9.41M $0.55

News headlines (Yahoo Finance, 1h cache)

BioCorRx, Inc. Announces Issuance of U.S. Patent Supporting Its Biodegradable Naltrexone Implant Technology
2026-03-11 12:30 · Yahoo
BioCorRx, Inc. Announces Initiation of Clinical Study by Majority-Owned Subsidiary BioCorRx Pharmaceuticals, Inc. Evaluating Long-Acting Naltrexone Implant With or Without Bupropion
2026-01-14 13:30 · Yahoo
BioCorRx Announces Appointment of Louis Lucido as Board Chair
2026-01-06 13:30 · Yahoo
BioCorRx Provides Update on OTC Markets Quotation Status and Planned Form S1 Filing
2025-12-24 13:30 · Yahoo
BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th
2025-12-10 13:35 · Yahoo
Life Sciences Virtual Investor Forum Agenda Announced for December 11th
2025-12-09 13:35 · Yahoo
BioCorRx, Inc. Announces Q3 2025 Results: Second Straight Quarter of Meaningful Revenue Driven by LUCEMYRA(R) Acquisition
2025-11-18 13:30 · Yahoo
Diamond Equity Research Initiates Coverage on BioCorRx®, Inc. (OTCQB: BICX)
2025-08-25 12:00 · Yahoo
BioCorRx Reports 3,985% Revenue Growth to $313K in the First Half of 2025 Driven by LUCEMYRA(R) (lofexidine) Sales
2025-08-14 18:25 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.